SEC Filing Summary

The filing details transactions made by Marino Garcia, CEO and President of Dianthus Therapeutics, Inc. On March 16, 2026, Garcia acquired 59,700 shares of common stock at $6.70 per share and an additional 5,592 shares at $17.88 per share. Concurrently, Garcia disposed of stock options for 59,700 shares with a strike price of $6.70 and 5,592 shares with a strike price of $17.88. Following these transactions, Garcia directly owns 65,292 shares of common stock and holds a total of 269,408 shares through unexercised stock options. The options have specific vesting schedules tied to continued service, with some vesting over three years from November 1, 2022, and others over four years from January 1, 2024.